For research use only. Not for therapeutic Use.
SGN-2FF is a potent and orally active inhibitor of fucosylation, directly inhibits fucosyltransferase activity. SGN-2FF possesses antitumor activity[1].
SGN-2FF (2-Fluorofucose) is an inhibitor of fucosylation, inhibits cellular fucosylation by depleting the fucosylation substrate GDP-fucose, and by direct inhibition of fucosyltransferases, and leads to the production of afucosylated glycoproteins including antibodies. SGN-2FF activates human T cells in an antigen-dependent manner[1].
SGN-2FF exhibits antitumor activity in multiple mouse tumor models, showing substantial tumor growth delay. SGN-2FF elevates the protective effect of a lymphoma vaccine in a syngeneic mouse model[1].
| Catalog Number | I020122 |
| CAS Number | 2089647-47-0 |
| Synonyms | (3S,4R,5S,6S)-3-fluoro-6-methyloxane-2,4,5-triol |
| Molecular Formula | C6H11FO4 |
| Purity | ≥95% |
| InChI | InChI=1S/C6H11FO4/c1-2-4(8)5(9)3(7)6(10)11-2/h2-6,8-10H,1H3/t2-,3-,4+,5-,6?/m0/s1 |
| InChIKey | IRKXGKIPOMIQOD-ZZWDRFIYSA-N |
| SMILES | CC1C(C(C(C(O1)O)F)O)O |
| Reference | [1]. Stephen C. Alley, et al. Abstract DDT02-02: SGN-2FF: A novel small molecule inhibitor of fucosylation with preclinical antitumor activity through multiple immune mechanisms. Cancer Res 2017;77(13 Suppl). |
